Two Main Cancer Biomarkers as Molecular Targets of Binase Antitumor Activity.
Elena DudkinaVera UlyanovaVioletta AsmandiyarovaValentina VershininaOlga N IlinskayaPublished in: BioMed research international (2024)
Cancer is frequently coupled with the disturbance of key signaling pathways. Aberrant activation of the mitogen-activated protein kinase (MAPK) signaling cascade, occurring in over 85% of cancers, is mainly caused by the genetic alterations of its main components-oncogenes EGFR and RAS, and plays a crucial role in cell fate. The importance of EGFR and RAS proteins in a variety of tumors suggests that they would be good therapeutic targets, but at present, no effective targeted therapy against these two oncogenes has been proven. Here, we show that ribonuclease from Bacillus pumilus (binase) inhibits MAPK signaling through direct interaction with EGFR and RAS proteins. This effect contributes to the antitumor potential of binase along with its enzymatic activity. Multitargeticity of binase prevents the development of drug resistance, which is considered a major obstacle to effective anticancer treatment.
Keyphrases
- small cell lung cancer
- signaling pathway
- tyrosine kinase
- epidermal growth factor receptor
- papillary thyroid
- cell fate
- wild type
- pi k akt
- squamous cell
- oxidative stress
- childhood cancer
- gene expression
- lymph node metastasis
- genome wide
- cell proliferation
- risk assessment
- dna methylation
- protein kinase
- induced apoptosis
- single molecule
- endoplasmic reticulum stress
- smoking cessation